Federico Cividini
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2019First federal award
$13.7MFederal grants as PI9 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
9 awards · $13.7M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 17, 2026 | NIH | SBIR Phase II CRI-103 gene therapy as Investigational New Drug for Dilated Cardiomyopathy | $1.2M | CARDIAC RSK3 INHIBITORS, LLC |
| Jul 15, 2024 | NIH | SBIR Phase II RSK3 Anchoring Disruptor Therapy for Heart Failure | $2.0M | CARDIAC RSK3 INHIBITORS, LLC |
| Sep 14, 2023 | NIH | SBIR Phase II RSK3 Anchoring Disruptor Therapy for Heart Failure | $2.0M | CARDIAC RSK3 INHIBITORS, LLC |
| Aug 12, 2023 | NIH | SBIR Phase II PP2A Anchoring Disruptor Therapy in Heart Failure | $1.2M | CARDIAC RSK3 INHIBITORS, LLC |
| Sep 1, 2022 | NIH | SBIR Phase II PP2A Anchoring Disruptor Therapy in Heart Failure | $3.1M | CARDIAC RSK3 INHIBITORS, LLC |
| May 27, 2022 | NIH | SBIR Phase II ShRNA-Based Targeting of mAKAPβ in Heart Failure | $885K | CARDIAC RSK3 INHIBITORS, LLC |
| Aug 27, 2021 | NIH | SBIR Phase II PP2A Anchoring Disruptor Therapy in Heart Failure | $437K | CARDIAC RSK3 INHIBITORS, LLC |
| May 15, 2021 | NIH | SBIR Phase II ShRNA-Based Targeting of mAKAPβ in Heart Failure | $2.6M | CARDIAC RSK3 INHIBITORS, LLC |
| Jul 24, 2019 | NIH | SBIR Phase II ShRNA-Based Targeting of mAKAPβ in Heart Failure | $332K | CARDIAC RSK3 INHIBITORS, LLC |
Peer ranks
Federal funding#25
Awards as PI#151
Patents#273
Companies
- CARDIAC RSK3 INHIBITORS, LLCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.